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Topical Review
A classification of chronic pain for ICD-11
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1. Introduction
Chronic pain has been recognized as pain that persists past
normal healing time5 and hence lacks the acute warning function
of physiological nociception.35 Usually pain is regarded as
chronic when it lasts or recurs for more than 3 to 6 months.29
Chronic pain is a frequent condition, affecting an estimated 20%
of people worldwide6,13,14,18 and accounting for 15% to 20% of
physician visits.25,28Chronic pain should receive greater attention
as a global health priority because adequate pain treatment is
a human right, and it is the duty of any health care system to
provide it.4,13
The current version of the International Classification of Diseases
(ICD) of the World Health Organization (WHO) includes some
diagnostic codes for chronic pain conditions, but these diagnoses
do not reflect the actual epidemiology of chronic pain, nor are they
categorized in a systematicmanner. The ICD is the preeminent tool
for coding diagnoses and documenting investigations or thera-
peuticmeasures within the health care systems of many countries.
In addition, ICD codes are commonly used to report target
diseases and comorbidities of participants in clinical research.
Consequently, the current lack of adequate coding in the ICD
makes the acquisition of accurate epidemiological data related to
chronic pain difficult, prevents adequate billing for health care
expenses related to pain treatment, and hinders the development
and implementation of new therapies.10,11,16,23,27,31,37
Responding to these shortcomings, the International Associ-
ation for the Study of Pain (IASP) contacted the WHO and
established a Task Force for the Classification of Chronic Pain.
The IASP Task Force, which comprises pain experts from across
the globe,19 has developed a new and pragmatic classification of
chronic pain for the upcoming 11th revision of the ICD. The goal is
to create a classification system that is applicable in primary care
and in clinical settings for specialized pain management.
A major challenge in this process was finding a rational
principle of classification that suits the different types of chronic
pain and fits into the general ICD-11 framework. Pain categories
are variably defined based on the perceived location (headache),
etiology (cancer pain), or the primarily affected anatomical system
(neuropathic pain). Some diagnoses of pain defy these classifi-
cation principles (fibromyalgia).
This problem is not unique to the classification of pain, but exists
throughout the ICD. The IASP Task Force decided to give first
priority to pain etiology, followed by underlying pathophysiological
mechanisms, and finally the body site. Developing thismultilayered
classificationwas greatly facilitated by a novel principle of assigning
diagnostic codes in ICD-11, termed “multiple parenting.” Multiple
parenting allows the same diagnosis to be subsumed under more
than 1 category (for a glossary of ICD terms refer to Table 1). Each
diagnosis retains 1 category as primary parent, but is cross-
referenced to other categories that function as secondary parents.
The new ICD category for “Chronic Pain” comprises the most
common clinically relevant disorders. These disorders were
divided into 7 groups (Fig. 1): (1) chronic primary pain, (2) chronic
cancer pain, (3) chronic posttraumatic and postsurgical pain, (4)
chronic neuropathic pain, (5) chronic headache and orofacial
pain, (6) chronic visceral pain, and (7) chronic musculoskeletal
pain. Experts assigned to each group are responsible for the
definition of diagnostic criteria and the selection of the diagnoses
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to be included under these subcategories of chronic pain. Thanks
to Bedirhan U¨stu¨n and Robert Jakob of the WHO, these pain
diagnoses are now integrated in the beta version of ICD-11
(http://id.who.int/icd/entity/1581976053). The Task Force is
generating content models for single entities to describe their
clinical characteristics. After peer review overseen by the WHO
Steering Committee,39 the classification of chronic pain will be
voted into action by the World Health Assembly in 2017.
2. Classification of chronic pain
Chronic pain was defined as persistent or recurrent pain lasting
longer than 3 months. This definition according to pain duration
has the advantage that it is clear and operationalized.
Optional specifiers for each diagnosis record evidence of
psychosocial factors and the severity of the pain. Pain severity
can be graded based on pain intensity, pain-related distress, and
functional impairment.
2.1. Chronic primary pain
Chronic primary pain is pain in 1 or more anatomic regions that
persists or recurs for longer than 3 months and is associated with
significant emotional distress or significant functional disability
(interference with activities of daily life and participation in social
roles) and that cannot be better explained by another chronic pain
condition. This is a new phenomenological definition, created
because the etiology is unknown for many forms of chronic pain.
Common conditions such as, eg, back pain that is neither
identified as musculoskeletal or neuropathic pain, chronic
widespread pain, fibromyalgia, and irritable bowel syndrome will
be found in this section and biological findings contributing to the
pain problemmay or may not be present. The term “primary pain”
was chosen in close liaison with the ICD-11 revision committee,
who felt this was the most widely acceptable term, in particular,
from a nonspecialist perspective.
2.2. Chronic cancer pain
Pain is a frequent and debilitating accompaniment of cancer8 that
as yet has not been represented in the ICD. The Task Force
decided to list it as a separate entity because there are specific
treatment guidelines.7,38 Chronic cancer pain includes pain
caused by the cancer itself (the primary tumor or metastases)
and pain that is caused by the cancer treatment (surgical,
chemotherapy, radiotherapy, and others). Cancer-related pain
will be subdivided based on location into visceral, bony (or
musculoskeletal), and somatosensory (neuropathic). It will be
described as either continuous (background pain) or intermittent
(episodic pain) if associated with physical movement or clinical
procedures. The treatment-related pain will be cross-referenced
from the chapters on postsurgical pain and neuropathic pain.
2.3. Chronic postsurgical and posttraumatic pain
Because pain that persists beyond normal healing is frequent after
surgery and some types of injuries, the entity of postsurgical and
posttraumatic pain was created. This is defined as pain that
develops after a surgical procedure or a tissue injury (involving any
trauma, including burns) and persists at least 3months after surgery
or tissue trauma26; this is a definition of exclusion, as all other causes
of pain (infection, recurring malignancy) as well as pain from a pre-
existing pain problem need to be excluded. In view of the different
causality, as well as from a medicolegal point of view, a separation
betweenpostsurgical pain andpain after all other trauma is regarded
as useful. Depending on the type of surgery, chronic postsurgical
pain is oftenneuropathic pain (on average30%of caseswith a range
from 6% to 54% and more).15 Pain including such a neuropathic
component is usually more severe than nociceptive pain and often
affects the quality of life more adversely.21
2.4. Chronic neuropathic pain
Chronic neuropathic pain is caused by a lesion or disease of the
somatosensory nervous system.20,22 The somatosensory ner-
vous system provides information about the body including skin,
musculoskeletal, and visceral organs. Neuropathic pain may be
spontaneous or evoked, as an increased response to a painful
stimulus (hyperalgesia) or a painful response to a normally
nonpainful stimulus (allodynia). The diagnosis of neuropathic pain
requires a history of nervous system injury, for example, by
a stroke, nerve trauma, or diabetic neuropathy, and a neuro-
anatomically plausible distribution of the pain.22 For the identifi-
cation of definite neuropathic pain, it is necessary to demonstrate
the lesion or disease involving the nervous system, for example,
by imaging, biopsy, neurophysiological, or laboratory tests. In
Figure 1. Organizational chart of Task Force, IASP, and WHO interactions. The IASP Task Force was created by the IASP council and its scope defined in direct
consultation of the chairs (R.D.T. and W.R.) with WHO representatives in 2012. The Task Force reports to the IASP Council on an annual basis.
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addition, negative or positive sensory signs compatible with the
innervation territory of the lesioned nervous structure must be
present.36 Diagnostic entities within this category will be divided
into conditions of peripheral or central neuropathic pain.
2.5. Chronic headache and orofacial pain
The International HeadacheSociety (IHS) has created a headache
classification17 that is implemented in full in the chapter on
neurology. This classification differentiates between primary
(idiopathic), secondary (symptomatic) headache, and orofacial
pain including cranial neuralgias. In the section on chronic pain,
only chronic headache and chronic orofacial pain will be included.
Chronic headache and chronic orofacial pain is defined as
headaches or orofacial pains that occur on at least 50% of the
days during at least 3 months. For most purposes, patients
receive a diagnosis according to the headache phenotypes or
orofacial pains that they currently present. The section will list the
most frequent chronic headache conditions.
The most common chronic orofacial pains are temporoman-
dibular disorders,32 which have been included in this subchapter
of chronic pain. Chronic orofacial pain can be a localized
presentation of a primary headache.2 This is common in the
trigeminal autonomic cephalalgias, less common in migraines,
and rare in tension-type headache. Several chronic orofacial
pains such as post-traumatic trigeminal neuropathic pain,3
persistent idiopathic orofacial pain, and burningmouth syndrome
are cross-referenced to, eg, primary chronic pain and neuro-
pathic pain. The temporal definition of “chronic” has been
extrapolated from that of chronic headaches.1
2.6. Chronic visceral pain
Chronic visceral pain is persistent or recurrent pain that originates
from the internal organs of the head and neck region and the
thoracic, abdominal, and pelvic cavities.24,33,34 The pain is usually
perceived in the somatic tissues of the body wall (skin, subcutis,
muscle) in areas that receive the same sensory innervation as the
internal organ at the origin of the symptom (referred visceral
pain).12 In these areas, secondary hyperalgesia (increased
sensitivity to painful stimuli in areas other than the primary site
of the nociceptive input) often occurs30; the intensity of the
symptom may bear no relationship with the extent of the internal
damage or noxious visceral stimulation.9 The section on visceral
pain will be subdivided according to the major underlying
mechanisms, ie, persistent inflammation, vascular mechanisms
(ischemia, thrombosis), obstruction and distension, traction and
compression, combined mechanisms (eg, obstruction and
inflammation concurrently), and referral from other locations.
Pain due to cancer will be cross-referenced to the chapter
chronic cancer pain and pain due to functional or unexplained
mechanisms to chronic primary pain.
2.7. Chronic musculoskeletal pain
Chronic musculoskeletal pain is defined as persistent or recurrent
pain that arises as part of a disease process directly affecting
bone(s), joint(s),muscle(s), or related soft tissue(s). According to the
constraints of the approach as described in the Introduction, this
category is therefore limited to nociceptive pain and does not
include pain that may be perceived in musculoskeletal tissues but
does not arise therefrom, such as the pain of compression
neuropathy or somatic referred pain. The entities subsumed in this
approach include those characterized by persistent inflammation
of infectious, autoimmune or metabolic etiology, such as
rheumatoid arthritis, and by structural changes affecting bones,
joints, tendons, or muscles, such as symptomatic osteoarthrosis.
Musculoskeletal pain of neuropathic originwill be cross-referenced
to neuropathic pain. Well-described apparent musculoskeletal
conditions forwhich the causes are incompletely understood, such
as nonspecific back pain or chronic widespread pain, will be
included in the section on chronic primary pain.
3. Outlook
Irrespective of its etiology, chronic pain is a major source of
suffering and requires special treatment and care. Our proposal
may not represent a perfect solution for the classification of all
manifestations of chronic pain. However, it does represent the first
systematic approach to implementing a classification of chronic
pain in the ICD. It is based on international expertise and
agreement, and consistent with the requirements of the ICD
regarding the structure and format of content models. The 7 major
categories of chronic pain were identified after considerable
research and discussion. They represent a compromise between
comprehensiveness and practical applicability of the classification
system. Several clinically important conditions that were neglected
in former ICD revisions will now be mentioned, eg, chronic cancer
pain or chronic neuropathic pain. Etiological factors, pain intensity,
and disability related to pain will be reflected. With the introduction
of chronic primary pain as a new diagnostic entity, the classification
recognizes conditions that affect a broad group of patients with
pain andwould be neglected in etiologically defined categories.We
hope that this classification strengthens the representation of
chronic pain conditions in clinical practice and research and
welcome comments to improve it further.
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Table 1
Glossary of ICD-11 terms.
WHO term Explanation
(Diagnostic) entity The unit of classification, eg, individual diagnoses and
diagnostic chapters
Content model A structured framework that contains all information
required to describe an entity within the ICD. A content
model contains information on an entity’s name, its
definition, the affected body system or structure, the
disease course, its etiology, treatment, and limitations in
physical, emotional, or social functioning associated
with the entity
Parent/child Entities are arranged in a hierarchical order, with
a “parent” entity at the top, eg, “chronic pain,” and child
entities subsumed underneath, eg, “chronic
neuropathic pain”. Child entities can be parent to the
next level, eg, “chronic neuropathic pain” is a parent
relative to “chronic peripheral neuropathic pain”
Multiple parenting Entities can have more than 1 parent. An entity such as
“chronic chemotherapy-induced pain” has, eg, “chronic
cancer pain” and “chronic neuropathic pain” as parents.
One of them is designated as the “primary” parent, but
the entity can be found under either heading. Multiple
parenting thus allows 1 entity to be included in 2 or more
diagnostic categories
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Appendix Structure of the chapter on chronic pain
Chronic pain (persistent or recurrent pain lasting longer than 3
months)
1. Chronic primary pain
1.1. Widespread chronic primary pain (including fibromyalgia
syndrome)
1.2. Localized chronic primary pain (including nonspecific back
pain, chronic pelvic pain)
1.x. Other chronic primary pain
1.z. Chronic primary pain not otherwise specified
2. Chronic cancer pain
2.1. Chronic pain due to cancer and metastases
2.2. Chronic chemotherapy-induced pain (primary parent:
chronic neuropathic pain)
2.3. Chronic pain due to cancer surgery (primary parent:
chronic postsurgical and posttraumatic pain)
2.4. Chronic pain due to radiotherapy
2.x. Other chronic pain related to cancer
2.z. Chronic cancer pain not otherwise specified
3. Chronic postsurgical and posttraumatic pain
3.1. Chronic postsurgical pain
3.2. Chronic posttraumatic pain
3.x. Other chronic postsurgical and posttraumatic pain
3.z. Chronic postsurgical and posttraumatic pain not otherwise
specified
4. Chronic neuropathic pain
4.1. Peripheral neuropathic pain
4.2. Central neuropathic pain
4.x. Other neuropathic pain
4.z. Neuropathic pain not otherwise specified
5. Chronic headache and orofacial pain
5.1. Chronic primary headaches*
5.2. Chronic secondary headaches*
5.3. Chronic orofacial pains†
5.z. Headache and orofacial pain not otherwise specified*
6. Chronic visceral pain
6.1. Chronic visceral pain from persistent inflammation
6.2. Chronic visceral pain from vascular mechanisms
6.3. Chronic visceral pain from obstruction/distension
6.4. Chronic visceral pain from traction/compression
6.5. Chronic visceral pain from combined mechanisms
6.6. Chronic visceral pain referred from other locations
6.7. Chronic visceral pain from cancer (primary parent: chronic
cancer pain)
6.8. Functional or unexplained chronic visceral pain (primary
parent: chronic primary pain)
6.x. Other chronic visceral pain
6.z. Chronic visceral pain not otherwise specified
7. Chronic musculoskeletal pain
7.1. Chronic musculoskeletal pain from persistent inflammation
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7.2. Chronic musculoskeletal pain from structural osteoartic-
ular changes
7.3. Chronic musculoskeletal pain due to disease of the
nervous system (All neuropathic pain will be classified
under 4. Chronic neuropathic pain. Here, other chronic
musculoskeletal pain originating from diseases of the
nervous system, eg, spastic pain will be listed.)
7.4. Chronic nonspecific musculoskeletal pain (primary parent:
chronic primary pain)
7.x. Other chronic musculoskeletal pain syndromes
7.z. Chronic musculoskeletal pain not otherwise specified
*These disorders have in part been renumbered as compared
with the ICHD-3. †#5.3 is not part of the ICHD-3.
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